Regulation of L-arginine uptake by Ca2+ in human platelets  by Giovine, Marco et al.
Regulation of L-arginine uptake by Ca2 in human platelets
Marco Giovine1, Maria Grazia Signorello1, Marina Pozzolini, Giuliana Leoncini*
Dipartimento di Medicina Sperimentale, sezione Biochimica, Universita' di Genova, Viale Benedetto XV 1, 16132, Genova, Italy
Received 19 August 1999; received in revised form 13 October 1999
Abstract L-Arginine uptake and Ca2+ changes in unstirred
platelets activated by thrombin, collagen and Ca2+ ionophore
A23187 were evaluated. Thrombin did not affect L-arginine
uptake at short incubation times (2^15 min), but at prolonged
times slowed down the amino acid transport. Collagen was
ineffective. A23187 decreased the L-arginine uptake in a dose-
dependent manner, producing the maximal inhibition at 5 WM. In
FURA 2-loaded platelets collagen did not modify Ca2+ basal
level, thrombin induced a late Ca2+ rise and A23187 dose-
dependently increased cytosolic Ca2+, eliciting the highest
increase at 5 WM. It is likely that L-arginine uptake is inversely
modulated by Ca2+ concentrations and is inhibited during
platelet stimulation with agonists which induce cytosolic Ca2+
elevation.
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1. Introduction
Nitric oxide (NO) is one of the most complex and widely
used messenger molecules in animals [1,2] and among its var-
ious activities it exerts an inhibitory e¡ect on platelet activa-
tion [3]. The regulation of platelet function is crucial to pre-
vent platelet hyperaggregation, thrombus formation and
strokes [4] and seems to be partially due to both endothelium
and endogenous derived NO [5,6]. In the last years an endog-
enous isoform of NO synthase (NOS) was puri¢ed and char-
acterised in platelets. This Ca2/calmodulin dependent enzyme
is active in the presence of the same cofactors as the other
constitutive NOS but it has a di¡erent molecular weight [7].
Despite the clear anti-aggregating e¡ect of NO, the e¡ective
role of the endogenous enzyme is still unclear. Moreover, a
particularly complicated problem is the regulation of the NO
pathway inside platelets. In fact, the presence of a Ca2-de-
pendent isoform is in contrast with the virtual absence of
endogenous NO production as a consequence of speci¢c
Ca2-mobilising stimuli. Lantoine et al. [8] observed the pro-
duction of endogenous NO in platelets stimulated with colla-
gen, while thrombin was unable to do it. The same authors
and other investigators observed that collagen does not mobi-
lise Ca2, while thrombin is known to increase intracellular
Ca2 concentration in platelets [8,9]. Similarly, Radomski et
al. observed that L-arginine, the natural substrate of NOS,
was able to inhibit, in a concentration-dependent manner,
platelet aggregation after collagen stimulation but curiously
the phenomenon did not occur after thrombin or A23187
stimulation [10].
Since the production of NO is strictly related to the avail-
ability of L-arginine, a possible mechanism of regulation of
NO synthesis could be related to the L-arginine transport sys-
tem.
In recent years, attention on L-arginine transport inside the
mammalian cells has been increasing [11]. There are various
known L-arginine plasma membrane transport systems and
their expression varies among di¡erent tissues and cell types.
System y has been identi¢ed as a speci¢c transport system
for L-arginine in human platelets, it is sodium-independent
and encoded by the CAT gene family [12]. Yet, little is known
about regulation of platelet L-arginine transport [12,13].
The experiments described in this paper were undertaken to
evaluate the role of Ca2 in the control of L-arginine uptake
in stimulated platelets. Agonists triggering di¡erent transduc-
tion pathways have been tested: thrombin, which activates
phospholipase C pathway and elevates cytosolic Ca2 by an
inositol 1,4,5-triphosphate-dependent release from internal
stores [14,15], collagen that can mobilise Ca2 only at high
concentrations [16] and A23187 which bypasses receptor-cou-
pling mechanisms and directly carries Ca2 across mem-
branes.
2. Materials and methods
2.1. Chemicals
L-Arginine, A23187, ionomycin, thrombin, Dowex 1U8-200 basic
anion exchanger resin, digitonin, EGTA and PGE1 were from Sigma.
1-[2-(5-Carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(2P-amino-
5P-methylphenoxy)-ethane-N,N,NP,NP-tetraacetic acid pentaacetoxy-
methylester (Fura 2/AM) was from Calbiochem-Novabiochem.
L-[2,3,4-3H]Arginine was from NEN Life Science Products. Collagen
was from Mascia Brunelli S.p.A. Titertek ¢lters were from Flow Lab-
oratories.
2.2. Blood collection and preparative procedures
Human blood from normal healthy volunteers, who declared to
have not taken drugs known to interfere with platelet function, was
collected in 130 mM aqueous trisodium citrate anticoagulant solution
(9:1). Washed platelets were prepared as previously described [17].
Brie£y, platelet-rich plasma, obtained by centrifugation of the whole
blood at 100Ug for 25 min, was centrifuged at 1000Ug for 20 min.
The pellet was washed once with pH 4.8 ACD solution (75 mM
trisodium citrate, 42 mM citric acid and 136 mM glucose). Platelets
obtained by centrifugation at 1000Ug for 20 min were resuspended in
Ca2 free pH 7.4 HEPES bu¡er, (145 mM NaCl, 5 mM KCl, 1 mM
MgSO4, 10 mM Glucose, 10 mM HEPES).
2.3. Puri¢cation of commercial L-[2,3,4-3H]arginine
Commercial L-[2,3,4-3H]arginine was puri¢ed to eliminate every
contaminating product such as ornitine and citrulline by chromatog-
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raphy on Dowex 1U8-200 basic anion exchanger resin. After the
consequent lyophilisation, puri¢ed L-[2,3,4-3H]arginine was resus-
pended to 1.0U106 cpm/Wl in 2% ethanol aqueous solution.
2.4. Measurement of L-arginine uptake
Washed platelets, resuspended in pH 7.4 HEPES bu¡er at 2.0U108/
ml, were incubated with PBS or agonists in the presence of 40 WM
L-arginine and 1 WCi/ml L-[2,3,4-3H]arginine in a Dubno¡ water bath
under gentle shaking, without stirring, at 37‡C. In these conditions
platelet activation, but not aggregation was induced by agonists. At
the indicated times aliquots of 1.0 ml incubation mixture were with-
drawn, immediately ¢ltered through a Titertek ¢lter and washed twice
with PBS. The radioactivity corresponding to the incorporated
L-[2,3,4-3H]arginine was directly measured by liquid scintillation
counting of the ¢lter in a Packard Tricarb 1600 TR.
2.5. Measurement of intracellular Ca2+ concentration
Intracellular Ca2 concentration was measured according to Roton-
do et al. [18]. Washed platelets (3.0U108/ml), resuspended in Ca2
free pH 7.4 HEPES bu¡er, were incubated with 1 WM FURA 2/AM,
for 45 min at 37‡C. 2 WM PGE1 and 1.0 mM EGTA were added
before centrifuging for 15 min at 1100Ug. The pellet, resuspended
at 2.0U108/ml in pH 7.4 HEPES bu¡er, was preincubated at 37‡C
for 2 min before the addition of the agonists. FURA 2-loaded platelet
£uorescence followed, 60 min at 37‡C in unstirred conditions in a
Perkin-Elmer £uorescence spectrometer model LS50B with excitations
at 340 nm and 380 nm and emission at 510 nm. The £uorescence of
fully saturated FURA 2 (Fmax) was obtained by lysing the cells with
50 WM digitonin in the presence of 2.0 mM Ca2, while Fmin was
determined by exposing the lysed platelets to 20 mM EGTA. The
£uorescence was fully quenched with 5 mM Mn2 to give the auto-
£uorescence value. A computer program combined with the £uores-
cence spectrometer converted data into cytosolic Ca2 concentration
([Ca2]i). The Kd value for FURA 2 and Ca2 was 140 nM.
3. Results
3.1. L-Arginine uptake in resting and activated platelets
The time-course of L-arginine uptake in resting and stimu-
lated platelets was studied. The data (Fig. 1A) show that
L-arginine uptake was not signi¢cantly modi¢ed in platelets
challenged by collagen or thrombin at short incubation times
(2^15 min). At prolonged incubation times (30^60 min) L-ar-
ginine uptake dose-dependently slowed down in thrombin-
treated platelets, while it behaved similarly to controls in col-
lagen-stimulated samples. The Ca2 ionophore A23187
blocked the transport activity almost completely, inducing a
limited increase only in platelets incubated for 2 min at 37‡C.
Addition of 2.0 mM EGTA to platelet suspensions completely
reversed the inhibition produced by thrombin or A23187 (Fig.
1B). The data suggest that Ca2 could be involved in the
L-arginine uptake regulation. Therefore, the e¡ects of
A23187 were analysed. As shown in Fig. 2, L-arginine uptake
was inhibited in a concentration dependent manner by
A23187. The Ca2 ionophore produced the maximal inhibi-
tion at 5 WM and higher concentrations up to 20 WM did not
change the inhibitory pro¢le. The same e¡ects as A23187 were
obtained in platelets stimulated by ionomycin (data not
shown). All these experiments were performed incubating
platelets in the presence of 40 WM L-arginine, but closely
similar inhibition pro¢les were observed at physiological con-
centration (100 WM) [19] of L-arginine. (data not shown).
3.2. Cytosolic Ca2+ changes in agonist-stimulated platelets
To investigate the relationship between L-arginine uptake
and cytosolic Ca2 concentrations, Ca2 changes were fol-
lowed for 60 min in unstirred platelet suspensions challenged
by the agonists, in the absence of external Ca2. Data shown
in Fig. 3 have been obtained after 30 min of incubation.
Stimulation of platelets by 5 Wg collagen did not increase
cytosolic Ca2 basal level (46 þ 12 nM). Platelet treatment
with A23187 produced a dose-dependent e¡ect on cytosolic
Ca2 elevation, that, at 5 WM A23187, reached the maximal
level corresponding to 151 þ 30 nM. Moreover, thrombin in-
duced a [Ca2]i rise corresponding to 78 þ 8 nM (0.1 U/ml
thrombin) or 110 þ 12 nM (5.0 U/ml thrombin). Nevertheless,
a di¡erent time course of [Ca2]i during 60 min was found in
platelets stimulated by A23187 or thrombin. In the ¢rst case
(A23187) [Ca2]i rose very rapidly (1 min) and was unchanged
during the whole incubation period. On the contrary, [Ca2]i
slowly increased, varying from 46 þ 12 nM to 105 þ 9 nM or
130 þ 15 nM after 60 min in platelets treated with 0.1 U/ml or
5.0 U/ml thrombin, respectively. In addition, under stirring
conditions, Ca2 rise was very early and reached 250 þ 75
nM or 550 þ 93 nM in the presence of the above-mentioned
thrombin concentrations.
4. Discussion
NO plays a fundamental role in the regulation of platelet
Fig. 1. Time-course of L-arginine uptake in resting and activated
platelets. Washed platelets (2.0U108/ml) were incubated with PBS
(F), 5 Wg collagen (S), 0.1 U/ml thrombin (R), 5.0 U/ml thrombin
(b) or 5 WM Ca2 ionophore A23187 (8) in the absence (A) or in
the presence of 2.0 mM EGTA (B). Data are the mean þ S.D. of
four experiments. * P6 0.0005; 3 P6 0.0025; # P6 0.05 vs control.
Fig. 2. E¡ect of Ca2 ionophore A23187 on L-arginine uptake.
Washed platelets (2.0U108/ml) were incubated with PBS (F), 0.05
WM A23187 (R), 0.1 WM A23187 (S), 1.0 WM A23187 (8), 5.0 WM
A23187 (b). Reported data are means þ S.D. of experiments per-
formed three times with similar results. * P6 0.0005; b P6 0.0025;

P6 0.005; 3 P6 0.05 vs control.
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aggregation [3]. A few years ago some authors evidenced that
NO production in these cells is catalysed by a Ca2-dependent
NOS activity [7,8,20,21]. Moreover, Radomsky et al. de-
scribed L-arginine’s ability to inhibit platelet aggregation in-
duced by arachidonic acid or ADP [10]. The same authors
also observed that L-arginine was unable to inhibit platelet
aggregation after thrombin or A23187 stimulation [10]. Sim-
ilarly Lantoine et al. measured the formation of NO in colla-
gen-stimulated platelets, while no traces of NO were detected
following thrombin activation [8]. These results suggest an
important role of [Ca2]i in the control of NO formation.
Therefore, we performed a series of experiments to demon-
strate that [Ca2]i regulates the L-arginine transport. The data
presented in this work, obtained in platelets incubated without
stirring in order to generate cell activation but not aggrega-
tion, show a dose-dependent negative e¡ect on L-arginine up-
take by A23187 (Fig. 2), a complete failure of collagen to
modify L-arginine transport and a late inhibition of this trans-
port after thrombin stimulation (Fig. 1A). The abrogation by
EGTA of the e¡ects generated by these agonists suggests a
basic role of [Ca2]i in the regulation of the L-arginine uptake
(Fig. 1B). Parallel experiments, carried out in platelets acti-
vated with collagen, thrombin or various ionophore concen-
trations were performed to evaluate [Ca2]i. Data showed the
absence of [Ca2]i increase in the presence of collagen, while
the dose-dependent A23187 e¡ects were rapid and constant.
The late inhibition of the L-arginine uptake after thrombin
stimulation could be due to gradual and long-time prolonged
Ca2 rise. In fact, in platelets incubated without stirring, the
Ca2 rise during the ¢rst 30 min of incubation was too low to
induce any inhibitory e¡ect, while only at longer incubation
times (30^60 min) the Ca2 increase was enough to modify the
L-arginine uptake. In particular, at 30 min of incubation the
[Ca2]i in thrombin-activated platelets ranged with the values
obtained in platelets stimulated by 0.1 WM and 0.5 WM
A23187 (Fig. 3). Moreover, intracellular arginine concentra-
tions measured in samples treated with 0.1 U/ml and 5.0 U/ml
thrombin (Fig. 1A) were similar to those obtained in 0.1WM
and 0.5 WM A23187-stimulated platelets (Fig. 2). The increase
of [Ca2]i elicited by 5 WM A23187 (151 þ 30 nM) was lower
than that mobilised during platelet aggregation [22], thereby
suggesting a complete stop of L-arginine uptake during this
process. Finally, the observed decrease in arginine intracellu-
lar concentration in platelets treated with thrombin could be
the consequence of both a reduced uptake and an increased
e¥ux. This hypothesis is suggested by data concerning y
arginine transporter described in mouse hepatocytes [23,24]
in which an arginine bidirectional £ux was shown.
All these data strengthen the hypothesis of a very re¢ned
control system of the L-arginine/NO pathway in human plate-
lets, in which [Ca2]i is at the same time the activator of
NOS and the inhibitor of the L-arginine uptake. This peculiar
behaviour may be justi¢ed by the analysis of the functions of
free intracellular Ca2, which is a potent stimulator of many
activation pathways [22] and may inversely control the NO
production after activation by speci¢c agonists.
The y L-arginine transport system is present in other cell
types, such as macrophages, in which it is subjected to a tran-
scriptional control [24]. It is interesting to notice that the
biosynthesis of the transporter is stimulated by lipopolysac-
charides, which is also a potent stimulator of inducible NOS
(iNOS) transcription [25]. Therefore, in macrophages a posi-
tive modulator of iNOS is also a positive modulator of the L-
arginine transporter. On the contrary, in platelets the positive
modulator of NOS is a negative modulator of the L-arginine
transport. These ¢ndings stress the recent observations that
strictly correlate the L-arginine metabolism with the NO pro-
duction in many cells operating in the circulatory system [11].
In particular these considerations suggest the fundamental
role of the L-arginine transport system in the various NO-
producing cells and speci¢cally in platelets in which the rap-
idity of events during the aggregation process requires simple
and multifunctional messengers.
Finally, the recent considerable interest in the potential
therapeutic properties of L-arginine in modulating NO bio-
availability in the vascular system and its possible applications
in patients with cardiovascular diseases [26] suggest further
experiments to better understand the molecular basis of this
peculiar control of L-arginine transport ¢rstly described in
platelets.
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